I was recently asked about the recent announcement that the RBL sponsoring a Brilacidin peer review journal article. Covid related studies are being expedited for publication. I would expect a publication submitted from a Regional Biodefense Labortory would be organized and carefully planned which would enable it to pass though the peer review process quickly...several weeks at the most.

That being said a quick search showed no publications have come out of the RBL labs related to therapeutics for Covid19.I encourage others to also look,I could not find any. A lot of publications exist for the process of studying and testing Covid 19. More studies will soon be published as there are hundreds listed in Clinicatrials.gov for Covid 19 therapeutics.

https://clinicaltrials.gov/ct2/results?cond=c...&dist=

Most of the recent publications regarding Covid 19 therapeutics come from self funded drug studies by their big pharmaceutical companies.

The above facts are IMO a demonstration of Brilacidin's strengths and unique properties.

This process of review would not in any way slow the development of Brilacidin in other studies, grants evaluations or partnerships or any other academic or business activity.

GLTA, Farrell